Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates.
Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS).
In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome)..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 751.4K | 
| Three Month Average Volume | 23.7M | 
| High Low | |
| Fifty-Two Week High | 25.9 USD | 
| Fifty-Two Week Low | 14.56 USD | 
| Fifty-Two Week High Date | 26 Aug 2024 | 
| Fifty-Two Week Low Date | 25 Apr 2024 | 
| Price and Volume | |
| Current Price | 24.44 USD | 
| Beta | 1 | 
| Relative Price Change | |
| Four Week Relative Price Change | 5.78% | 
| Thirteen Week Relative Price Change | 23.03% | 
| Twenty-Six Week Relative Price Change | 6.56% | 
| Fifty-Two Week Relative Price Change | -15.53% | 
| Year-to-Date Relative Price Change | -3.83% | 
| Price Change | |
| One Day Price Change | 0.16% | 
| Thirteen Week Price Change | 31.68% | 
| Twenty-Six Week Price Change | 17.16% | 
| Five Day Price Change | -1.33% | 
| Fifty-Two Week Price Change | 5.85% | 
| Year-to-Date Price Change | 13.89% | 
| Month-to-Date Price Change | 0.29% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.44987 USD | 
| Book Value Per Share (Most Recent Quarter) | 9.69128 USD | 
| Tangible Book Value Per Share (Last Fiscal Year) | 7.44987 USD | 
| Tangible Book Value Per Share (Most Recent Quarter) | 9.69128 USD | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.27679 USD | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.40612 USD | 
| Revenue Per Share (Trailing Twelve Months) | 0.00853 USD | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD | 
| Dividend Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend Per Share (5 Year) | -99999.99 USD | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.05717 USD | 
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.85389 USD | 
| Normalized (Last Fiscal Year) | -1.05717 USD | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.05717 USD | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.85389 USD | 
| Including Extraordinary Items (Last Fiscal Year) | -1.05717 USD | 
| Including Extraordinary Items (Trailing Twelve Months) | -2.85389 USD | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 7.47557 USD | 
| Cash Per Share (Most Recent Quarter) | 6.26063 USD | 
| Cash Flow Per Share (Last Fiscal Year) | -0.93541 USD | 
| Cash Flow Per Share (Trailing Twelve Months) | -2.7681 USD | 
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.70712 USD | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -72 | 
| Cash Flow Revenue (Trailing Twelve Months) | -31,736 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -33,119.50% | 
| Pretax Margin (Last Fiscal Year) | -43.93% | 
| Pretax Margin (5 Year) | -104.51% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% | 
| Gross Margin (Trailing Twelve Months) | -99,999.99% | 
| Gross Margin (5 Year) | -99,999.99% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -59.51% | 
| Operating Margin (Trailing Twelve Months) | -37,938.04% | 
| Operating Margin (5 Year) | -115.73% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -43.94% | 
| Net Profit Margin (Trailing Twelve Months) | -33,121.86% | 
| Net Profit Margin (5 Year) | -104.50% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 5.22% | 
| Tangible Book Value (5 Year) | 13.52% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% | 
| Revenue Growth (3 Year) | 20.67% | 
| Revenue Change (Trailing Twelve Months) | -99.63% | 
| Revenue Per Share Growth | 11.53% | 
| Revenue Growth (5 Year) | -0.51% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | 30.70% | 
| Total Debt (5 Year) | -99,999.99% | 
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -145.08% | 
| EPS Change (Trailing Twelve Months) | -163.84% | 
| EPS Growth (3 Year) | -99,999.99% | 
| EPS Growth (5 Year) | -99,999.99% | 
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% | 
| EBITDA (5 Year Interim) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 | 
| Price to Tangible Book (Most Recent Quarter) | 3 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | -896,044,000 | 
| Net Debt (Last Fiscal Year) | -1,034,511,000 | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 11 | 
| Price to Sales (Trailing Twelve Months) | 2.8K | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 | 
| PE Normalized (Last Fiscal Year) | -100,000 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 1.4K | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 412 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% | 
| Dividend Yield | -99,999.99% | 
| Current Dividend Yield | 0.00% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 | 
| Price to Book (Most Recent Quarter) | 3 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 | 
| Long Term Debt to Equity (Most Recent Quarter) | 0 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% | 
| Payout Ratio (Trailing Twelve Months) | -99,999.99% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 | 
| Quick Ratio (Most Recent Quarter) | -100,000 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 14 | 
| Current Ratio (Most Recent Quarter) | 12 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -370,930,000 | 
| Free Cash Flow (Trailing Twelve Months) | -402,099,000 | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 | 
| Net Interest Coverage (Trailing Twelve Months) | -100,000 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 | 
| Total Debt to Equity (Most Recent Quarter) | 0 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -11.11% | 
| Return on Assets (Trailing Twelve Months) | -29.89% | 
| Return on Assets (5 Year) | -14.98% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -14.01% | 
| Return on Equity (Trailing Twelve Months) | -32.61% | 
| Return on Equity (5 Year) | -20.47% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -13.37% | 
| Return on Investment (Trailing Twelve Months) | -31.50% | 
| Return on Investment (5 Year) | -17.71% |